Gainers

• IM Cannabis (NASDAQ:IMCC) stock moved upwards by 36.0% to $0.37 during Monday's after-market session. The market value of their outstanding shares is at $2.0 million.
• High Tide (NASDAQ:HITI) shares moved upwards by 15.99% to $2.61. The company's market cap stands at $203.0 million. The company's, Q2 earnings came out today.
• XTL Biopharmaceuticals (NASDAQ:XTLB) stock increased by 8.69% to $2.5. The company's market cap stands at $5.0 million.
• Lexaria Bioscience (NASDAQ:LEXX) shares rose 7.26% to $0.65. The market value of their outstanding shares is at $15.2 million.
• Anixa Biosciences (NASDAQ:ANIX) shares increased by 7.25% to $2.66. The company's market cap stands at $84.0 million. The company's, Q2 earnings came out 3 days ago.
• Cosmos Health (NASDAQ:COSM) stock moved upwards by 6.28% to $0.25. The company's market cap stands at $13.0 million.

Losers

• PRF Technologies (NASDAQ:PRFX) stock fell 25.3% to $1.86 during Monday's after-market session. The company's market cap stands at $1.1 million.
• Redhill Biopharma (NASDAQ:RDHL) shares declined by 12.05% to $0.73. The company's market cap stands at $4.2 million.
• Creative Medical Tech (NASDAQ:CELZ) stock fell 11.3% to $2.12. The market value of their outstanding shares is at $8.0 million.
• Alvotech (NASDAQ:ALVO) stock declined by 10.38% to $3.8. The market value of their outstanding shares is at $1.3 billion.
• Scinai Immunotherapeutics (NASDAQ:SCNI) stock decreased by 9.12% to $0.33. The market value of their outstanding shares is at $1.3 million.
• Regentis Biomaterials (AMEX:RGNT) shares fell 8.11% to $8.64. The market value of their outstanding shares is at $7.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.